Exosome Release Screening for AMD Therapeutics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating age-related macular degeneration (AMD) are inefficient, particularly for dry AMD, which progresses slowly and lacks effective treatments, and existing methods for identifying therapeutic compounds are time-consuming, taking years to show minor effects, whereas wet AMD requires rapid intervention to prevent significant vision loss.
Innovation Solution
A method involving the culturing of retinal pigment epithelium cells under hypoxic conditions to measure exosome release, correlating it with AMD onset and severity, and using G-protein coupled receptor GPR143 agonists like L-DOPA to reduce exosome release as a candidate therapeutic approach for treating and preventing AMD progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used to identify therapeutic compounds for AMD, then treatment effectiveness may be improved, but the screening process takes years to show effects
Solution Approach 1:
The patent extracts and measures exosome release from RPE cells as a specific biomarker to screen for AMD therapeutic compounds. By focusing on this extracted measurable parameter rather than waiting for overall disease progression, the screening process is accelerated from years to hours while maintaining treatment effectiveness evaluation
Solution Approach 2:
The patent induces hypoxia in RPE cells beforehand to trigger exosome release, creating a preliminary state that amplifies the biological response. This preliminary action allows therapeutic compounds to be screened based on their ability to modulate exosome release under controlled stress conditions, providing rapid feedback on potential efficacy
2Reliability
If clinical trials are conducted for dry AMD, then treatment efficacy can be evaluated, but the trial duration must be at least 7-9 years to see minor effects
Solution Approach 1:
The patent changes the measurement parameter from long-term clinical outcomes to short-term exosome release metrics. By measuring exosome concentration and composition in cell culture supernatants after brief hypoxic exposure, the method accelerates efficacy evaluation from years to hours while maintaining reliability through consistent biomarker measurement
3Reliability
If wet AMD is treated with intraocular injections to inhibit VEGF, then vision loss can be prevented, but the treatment is expensive
Solution Approach 1:
The patent develops a universal screening platform using RPE cell cultures and exosome measurement that can evaluate multiple potential therapeutic compounds simultaneously. This multi-functional approach identifies various mechanisms of action (not limited to VEGF inhibition) that could prevent AMD progression, potentially reducing reliance on expensive monoclonal antibody injections
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for rapid screening of therapeutic compounds within 30 minutes to 4 hours, identifying potential treatments that can reduce exosome release, thereby addressing the slow progression of dry AMD and the urgent need for wet AMD intervention, and is scalable for industry use.
Implementation Method 1
the level of exosome release from the RPE cells may be measured after incubation in a hypoxic environment with candidate therapeutic compositions
Data Source
AI summary
Methods and systems for screening therapeutic compositions for the treatment of age-related macular degeneration (AMD) or for the prevention of progression of AMD, wherein retinal pigment epithelium cells (RPE) are cultured and the level of hypoxia-induced exosome release from the RPE cells is subsequently measured. In the present invention, the level of hypoxia-induced exosome release can be correlated with AMD onset and severity.